Drug intelligence / Profile preview

Septimeb

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous

Overview

Septimeb is a new herbal-derived remedy that has been recently approved for its potential immunomodulatory effects. It is being evaluated as an adjunct to standard treatment for severe sepsis, with the aim of improving inflammatory biomarkers and mortality rates in affected patients.

Brand names: Septimeb
Other names: septimomab

Beyond the preview

Go deeper on Septimeb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Septimeb.

Explore the full profile